Table of Contents

Metformin is best known as a first-line treatment for type 2 diabetes, yet it’s quietly gained attention for another reason, which is its potential to support weight loss. Researchers have noticed that some people lose a modest but steady amount of weight while taking it, even when it’s not prescribed for that purpose.

Clinical data support this observation. In the Diabetes Prevention Program (DPP) and other large trials, participants taking metformin lost an average of 2 to 5 kg (~4.4 to 11 lbs) and often maintained that change for years. These results have prompted growing interest in whether metformin might benefit those who struggle with weight linked to insulin resistance, prediabetes, or PCOS.

This article explores what science has found so far, how metformin influences appetite and metabolism, what kind of weight changes you can realistically expect, and whether it’s a safe option for weight management.

Key Takeaways

  • Metformin is not mainly a weight loss drug. It remains the first-line therapy for type 2 diabetes.
  • Weight loss is a side benefit. The drop in weight is usually small but steady and lasts as long as you keep taking the medicine.
  • Metformin helps your body use sugar better, lowers insulin levels, reduces hunger, and changes gut bacteria in ways that support small weight changes.
  • Doctors may use metformin off-label for certain cases. It’s sometimes given to people with prediabetes, PCOS, or weight gain from antipsychotic drugs.
  • Most people tolerate it well, but stomach issues like diarrhea or nausea are common, especially at first.

Is metformin a weight loss drug?

No, metformin is a prescription medication commonly used to manage type 2 diabetes. It is available in both immediate-release and extended-release forms and is sometimes prescribed in combination with other glucose-lowering agents.

According to the American Diabetes Association (ADA), metformin is the preferred first-line treatment for adults and children aged 10 and older.

Current guidelines suggest that if the hemoglobin A1C (HbA1c) level is below 9% at diagnosis, metformin alone is usually sufficient. If the HbA1c level is above 9%, doctors often combine metformin with another medication to help achieve target blood sugar levels.

Metformin

Does metformin cause weight loss?

Yes, doctors first observed this trend in their patients and later tested metformin in clinical trials involving people with diabetes, prediabetes, polycystic ovary syndrome (PCOS), and even those who gained weight from antipsychotic medications. Across these studies, metformin led to modest but steady weight loss.

It’s not as dramatic as what’s seen with newer weight-loss drugs, but its effects are gradual, sustainable, and tend to last as long as you keep taking it.

How does metformin help you lose weight?

White tablets wrapped with waist measuring tape

Several processes in the body work together to support small, steady weight changes.

1. It helps the body handle sugar better

Metformin lowers the amount of glucose the liver makes and helps tissues respond more effectively to insulin.

When insulin levels become more balanced, some people notice reduced hunger and less fat buildup. These changes can make it easier to lose a small amount of weight over time, especially when paired with healthy eating and regular activity.

2. Appetite signals trend down

In two separate clinical trials, scientists found that metformin raises the levels of a hormone called GDF15 (growth/differentiation factor 15) in the blood. This hormone acts on the brainstem to reduce appetite and food intake, which leads to gradual weight loss.

They confirmed this by testing it in mice. When normal mice were given metformin, their GDF15 levels went up, especially in tissues like the intestine and kidney. These mice were protected from gaining weight even when fed a high-fat diet. But when the same experiment was done on mice that didn’t have GDF15 or its receptor (called GFRAL), metformin no longer prevented weight gain.

Another study found that metformin can raise the levels of a molecule called Lac-Phe, which appears to contribute to the appetite-suppressing effects.

Researchers noticed that Lac-Phe levels go up after meals, similar to hormones like ghrelin and leptin, which help regulate hunger. The findings showed that both mice and humans experienced an increase in Lac-Phe after taking metformin.

The study went further, showing that even a single dose of metformin can increase Lac-Phe levels. This effect was seen not only in people with type 2 diabetes but also in healthy individuals, suggesting that the change is due to the drug itself, and not the disease.

3. Effects in the gut

While it was once thought to work mainly through the liver, newer studies show that metformin also affects the gut microbiota, which is the community of microorganisms living in our digestive tract.

The intestinal microbiota functions almost like an additional organ that supports our body’s overall health and balance.

Several studies have observed that metformin can do the following:

    • increase the abundance of beneficial bacteria such as Akkermansia
    • boost short-chain fatty acid (SCFA)-producing microbes
    • alter gene expression in certain bacterial groups

Many of metformin’s benefits appear to come from its effects on these gut bacteria. However, how metformin and the microbiota interact is still not fully understood, and further research is needed to explain this connection.

Can metformin be used for weight loss?

Doctors sometimes prescribe metformin off-label to help manage weight in specific situations. Common scenarios include:

    • people with prediabetes and higher body weight
    • polycystic ovary syndrome with insulin resistance
    • weight gain linked to antipsychotic treatment

It’s also the only medication recommended by the ADA for people with prediabetes to help delay or prevent the onset of type 2 diabetes.

Note that if metformin is used for weight management, it is not a stand-alone solution. Best results come when the medicine runs alongside changes in eating patterns, movement, and sleep.

In diabetes prevention studies, researchers compared people taking metformin and those doing an intensive lifestyle intervention, which included diet and exercise changes. After the first year, about 29% of people on metformin lost at least 5% of their weight, while about 63% of those in the lifestyle group reached that goal.

Is metformin safe for weight loss?

Metformin has been trusted for decades in diabetes treatment and prevention, with a strong record of safety. Most people tolerate it well, especially when doses start low and increase gradually. However, there are still a few safety points to keep in mind.

1. Digestive symptoms

Stomach-related side effects like diarrhea, nausea, and vomiting are fairly common, affecting up to about 30% of people who use metformin.

Taking the medicine with food usually helps. The extended-release version also tends to be gentler on the stomach and can make it easier to stay consistent due to its once-daily dosing convenience.

Researchers reviewed results from 21 observational studies involving people with type 2 diabetes who used metformin. The most common side effect was diarrhea, affecting about 7% of patients. Other reported issues included:

    • bloating
    • abdominal pain
    • vomiting
    • constipation

When comparing the two types of metformin, people taking the extended-release (XR) version had fewer digestive side effects than those on the immediate-release (IR) version.

Another study found that after switching from IR to XR metformin, the rate of stomach-related side effects fell from 26% to 12%, while diarrhea cases dropped from 18% to 8%.

2. Vitamin B12 deficiency

Taking metformin for a long time can sometimes lower vitamin B12 levels, especially when the dose is higher. This vitamin is vital for several functions in the body, including:

    • making DNA and red blood cells
    • keeping the nervous system healthy
    • supporting the metabolism of fats and amino acids

In one study, researchers found that each additional year of metformin use raised the chance of deficiency by about 5%. People who had used metformin for four years or more were 41% more likely to have low B12 levels than those who used it for a shorter time. Metformin users were also 27% more likely to have borderline low B12 levels.

Another study had similar findings. People who had used metformin for four years or longer were 67% more likely to have vitamin B12 deficiency compared to those who never took metformin, and 38% more likely to have low B12 than people who used metformin for a shorter time.

When vitamin B12 levels drop, symptoms can appear gradually. Common signs include:

    • nausea
    • loss of appetite
    • weight loss
    • swollen tongue (glossitis)

It can also lead to megaloblastic anemia, which causes fatigue, weakness, and pale skin. If left untreated, low B12 can affect the nervous system, leading to numbness, balance problems (ataxia), memory issues, mood changes, or even depression and dementia.

If any of these symptoms show up, it’s a good idea to have B12 levels checked. If a deficiency is found, it may be corrected with supplements.

3. Lactic acidosis

Metformin includes a black box warning (the strongest type of safety warning) for a rare but serious side effect called lactic acidosis. This condition happens in about 1 out of every 30,000 people who take the drug.

Lactic acidosis occurs when too much lactic acid builds up in the body, and the body can’t clear it fast enough. This causes the blood to become too acidic, which can lead to symptoms like:

    • tiredness
    • shortness of breath
    • stomach discomfort
    • confusion

Certain conditions make this reaction more likely, such as kidney or liver problems, older age, heavy alcohol use, surgery, or poor oxygen levels. These factors interfere with how the body processes and removes lactic acid.

People taking metformin are also advised to avoid drinking too much alcohol and to tell their doctor if they develop any of these risk factors. Although lactic acidosis is very rare, it can be life-threatening if it occurs, leading to low blood pressure, low body temperature, or even death if not treated quickly.

How much weight will you lose on metformin?

Woman measuring her waist with measuring tape

For general weight management, its effect tends to be mild, so expectations should remain realistic.

In adults at risk for diabetes

One of the most studied trials on metformin and weight loss is the Diabetes Prevention Program and its long-term follow-up. On average, people who took metformin lost 2-3% of their body weight, while those on placebo stayed roughly the same.

About 29% of metformin users lost at least 5% of their starting weight after the first year, compared with 13% of those taking placebo. Waist size also went down by about 2 cm (0.8 in).

After two years, those who stayed on the medication remained 3.5% below their starting weight, while less consistent users regained most of it. More importantly, no safety concerns were reported during the 10-year follow-up.

In overweight or obese individuals without diabetes

In one study, overweight and obese adults took metformin for six months at doses of up to 2,500 mg per day. By the end of the study, participants lost an average of 5.8 kg (12.8 lbs), which was roughly 5.6% of their body weight. Those with insulin resistance tended to lose more weight than those whose insulin levels were already normal.

Another large analysis looked at whether metformin helps people without diabetes, particularly those who are overweight, obese, or have fatty liver disease (NAFLD).

Researchers reviewed 49 clinical trials and found that metformin led to about a 2.5% reduction in body weight. The doses used in these studies typically ranged from 500 to 2,550 mg per day, with an average effective dose near 1,700 mg daily.

In children and teens with obesity, results were more limited. One review found that after about six months of treatment, those taking metformin had an average BMI drop of 1.38 points compared with those who did not take it. However, this effect faded in studies lasting a year or longer. Other research showed a smaller but similar improvement, about a 0.86-point reduction in BMI compared with placebo.

In women with polycystic ovary syndrome

PCOS is often linked to insulin resistance, making weight management a challenge for many women. Several systematic reviews show that metformin can reduce body weight and BMI while also improving both metabolic health and reproductive function.

The amount of weight lost tends to be modest, but the results are consistent across studies.

In one study, researchers followed 83 women with PCOS for eight months. Some were obese (BMI 30-37), and others were morbidly obese (BMI 37 or higher). Participants were randomly assigned to take either 1,500 mg or 2,550 mg of metformin daily.

Among those who were obese, women taking the higher dose lost about 3.6 kg (7.9 lbs), compared with 1.5 kg (3.3 lbs) in the lower-dose group. In the morbidly obese group, weight loss was similar for both doses, around 3.8 to 3.9 kg (8.4 to 8.6 lbs).

Metformin also helped reduce certain hormones, such as androstenedione, which is often elevated in PCOS, and showed improvements in cholesterol and other blood markers.

Another large review examined 24 clinical trials involving 564 women with PCOS treated with metformin. Across these studies, women experienced several measurable improvements:

    • About 3.13 kg (6.9 lbs) of weight loss
    • About 0.82 units of BMI reduction
    • Lower blood sugar levels
    • Reduced LDL (“bad”) cholesterol
    • Decreased male hormone levels, including testosterone, androstenedione, and 17-hydroxyprogesterone, which are linked to acne and excess hair growth
    • Improved fertility, with women on metformin being three times more likely to become pregnant compared with those taking placebo

In people who gained weight from antipsychotic medicines

Weight gain is a common side effect of many antipsychotic drugs, and it can increase the risk of diabetes and other metabolic problems.

Research shows that adding metformin can help counter this problem. This can be an important strategy when lifestyle changes alone are not enough.

In a 2016 study, patients taking both antipsychotics and metformin lost an average of 3.3 kg (7.3 lbs) more than those not taking metformin. Their BMI dropped by about 1.1 points, and their insulin sensitivity improved.

A more recent study confirmed that metformin is the only medication proven to prevent weight gain caused by antipsychotics. When started at the same time as an antipsychotic, it reduced weight gain by around 4 kg (8.8 lbs) compared to those who didn’t take it.

Because of these findings, new guidelines recommend:

    • Starting metformin alongside an antipsychotic, or
    • Adding it later if weight gain becomes noticeable.

Experts rated these recommendations as strong, suggesting that metformin can be a practical and effective option for managing antipsychotic-related weight gain.

How fast does metformin work for weight loss?

It’s best to think of metformin’s effect on weight as a slow and steady process. Most people see changes in the first three to six months, then things start to level out. After that, any extra loss tends to come slowly, and on average, long-term results amount to a small percentage of your starting weight. The real difference often comes down to how consistent you are with taking it.

Beyond the medication itself, several individual and lifestyle factors affect your results:

  • Your baseline insulin resistance and metabolic health – People with higher fasting insulin, insulin resistance, or conditions like PCOS often see faster or more noticeable weight changes. This is because metformin directly improves insulin sensitivity and lowers circulating insulin levels, which reduces fat storage.
  • Your diet and eating habits – Metformin can reduce appetite, but that effect only helps if you respond by eating less or choosing lower-calorie foods. Diets rich in fiber, lean protein, and whole grains tend to enhance weight-loss effects, while processed or high-sugar diets can cancel them out.
  • Physical activity – Exercise increases how well your body uses glucose and burns fat. Combining metformin with even moderate activity, like walking, swimming, or resistance training, usually accelerates weight reduction compared to using the drug alone.
  • Other medications you take – Some drugs, like corticosteroids, can cause weight gain that counteracts metformin’s effects.
  • Your gut tolerance and dose – If nausea, diarrhea, or bloating cause you to skip doses or eat irregularly, your progress can slow. Adjusting to the medication gradually or switching to extended-release metformin can improve consistency, which is important for steady results.
  • Sleep and stress levels – Poor sleep and chronic stress elevate cortisol and insulin levels, which promote fat storage, especially around the abdomen. Managing stress, getting enough rest, and maintaining a stable sleep schedule can make metformin more effective.
  • Age, sex, and hormonal balance – Hormonal factors, like menopause or low testosterone, can influence metabolism and how efficiently your body burns fat.

Bottom line

Metformin can support gradual weight loss in some people, particularly those with insulin resistance or medication-related weight gain. The effect is usually modest and builds slowly over time.

The best way to lose weight with metformin is to take it consistently and pair it with steady lifestyle habits. It’s generally safe when monitored properly, especially with periodic checks of vitamin B12 levels and kidney function. Talk with your clinician to see if metformin aligns with your health needs and long-term goals.

Related Articles

Frequently Asked Questions

Metformin is best taken with meals to reduce stomach upset and improve absorption. If you’re using the immediate-release form, take it with breakfast and dinner, or once with your evening meal if on extended-release.

Metformin doesn’t cause rapid weight loss on its own. The process is gradual and works best when combined with a calorie-controlled diet, regular physical activity, and proper sleep. Studies show that consistent users may lose 1.5-5 kg over several months.

Yes, Glucophage (a brand of metformin) may lead to modest weight loss. Since it contains the same active ingredient, the weight changes observed in metformin studies generally apply to Glucophage users as well.

Glucophage is not officially approved as a weight loss medication, but doctors sometimes prescribe it off-label for people with insulin resistance, PCOS, or medication-related weight gain. Its use should always be under medical supervision, especially in non-diabetic individuals.

Start with a low dose, such as 500 mg once daily with food, and increase gradually as advised by your clinician. Take it consistently at the same time each day to maintain steady blood levels. Pairing it with balanced meals and exercise improves results.

A 500 mg dose can support mild weight loss, especially if combined with lifestyle changes. However, research shows that higher daily doses, typically around 1,700 mg or more, tend to produce greater and more consistent weight loss over time.

No, metformin is not a diet pill. It’s a prescription drug for managing blood sugar in type 2 diabetes, though some people experience modest weight loss as a side effect.

Sources

Corcoran, C., & Jacobs, T. F. (2023, August 17). Metformin. StatPearls – NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK518983/

Coll, A. P., Chen, M., Taskar, P., Rimmington, D., Patel, S., Tadross, J. A., Cimino, I., Yang, M., Welsh, P., Virtue, S., Goldspink, D. A., Miedzybrodzka, E. L., Konopka, A. R., Esponda, R. R., Huang, J. T., Tung, Y. C. L., Rodriguez-Cuenca, S., Tomaz, R. A., Harding, H. P., . . . O’Rahilly, S. (2019). GDF15 mediates the effects of metformin on body weight and energy balance. Nature, 578(7795), 444–448. https://doi.org/10.1038/s41586-019-1911-y

Scott, B., Day, E. A., O’Brien, K. L., Scanlan, J., Cromwell, G., Scannail, A. N., McDonnell, M. E., Finlay, D. K., & Lynch, L. (2024). Metformin and feeding increase levels of the appetite-suppressing metabolite Lac-Phe in humans. Nature Metabolism, 6(4), 651–658. https://doi.org/10.1038/s42255-024-01018-7

Wang, Y., Jia, X., & Cong, B. (2024). Advances in the mechanism of metformin with wide-ranging effects on regulation of the intestinal microbiota. Frontiers in Microbiology, 15. https://doi.org/10.3389/fmicb.2024.1396031

Apolzan, J. W., Venditti, E. M., Edelstein, S. L., Knowler, W. C., Dabelea, D., Boyko, E. J., Pi-Sunyer, X., Kalyani, R. R., Franks, P. W., Srikanthan, P., & Gadde, K. M. (2019). Long-Term weight loss with metformin or lifestyle intervention in the Diabetes Prevention Program Outcomes study. Annals of Internal Medicine, 170(10), 682. https://doi.org/10.7326/m18-1605

Nabrdalik, K., Hendel, M., Irlik, K., Kwiendacz, H., ?oniewski, I., Bucci, T., Alam, U., Lip, G. Y. H., Gumprecht, J., & Skonieczna-?ydecka, K. (2024). Gastrointestinal adverse events of metformin treatment in patients with type 2 diabetes mellitus: a systematic review and meta-analysis with meta-regression of observational studies. BMC Endocrine Disorders, 24(1). https://doi.org/10.1186/s12902-024-01727-w

Blonde, L., Dailey, G. E., Jabbour, S. A., Reasner, C. A., & Mills, D. J. (2004). Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study. Current Medical Research and Opinion, 20(4), 565–572. https://doi.org/10.1185/030079904125003278

Hurley-Kim, K., Vu, C. H., Dao, N. M., Tran, L. C., McBane, S., Lee, J., & Sepassi, A. (2023). Effect of metformin use on vitamin B12 deficiency over Time (EMBER): a Real-World Evidence Database study. Endocrine Practice, 29(11), 862–867. https://doi.org/10.1016/j.eprac.2023.06.013

Sepassi, A., Wang, J., Yankowski, S., Enkoji, A., Okenwa, M., Morello, C. M., & Hurley-Kim, K. (2025). Associations between long-term metformin use, the risk of vitamin B12 deficiency, and neuropathy: An All of Us research Program study. Diabetes Research and Clinical Practice, 228, 112424. https://doi.org/10.1016/j.diabres.2025.112424

Ramzan, N. U. H., Shahjahan, K., Dhillon, R. A., Khan, N. T. A., Hashmat, M. B., Anwer, M. U., Ahmed, D., Afzal, F., Tahir, M. M., & Muzaffar, A. (2024). Vitamin B12 deficiency in patients taking metformin: pathogenesis and recommendations. Cureus. https://doi.org/10.7759/cureus.68550

Seifarth, C., Schehler, B., & Schneider, H. (2012). Effectiveness of Metformin on Weight Loss in Non-Diabetic Individuals with Obesity. Experimental and Clinical Endocrinology & Diabetes, 121(01), 27–31. https://doi.org/10.1055/s-0032-1327734

Haber, R., Zarzour, F., Ghezzawi, M., Saadeh, N., Bacha, D. S., Jebbawi, L. A., Chakhtoura, M., & Mantzoros, C. S. (2024). The impact of metformin on weight and metabolic parameters in patients with obesity: A systematic review and meta?analysis of randomized controlled trials. Diabetes Obesity and Metabolism, 26(5), 1850–1867. https://doi.org/10.1111/dom.15501

McDonagh, M. S., Selph, S., Ozpinar, A., & Foley, C. (2013). Systematic review of the benefits and risks of metformin in treating obesity in children aged 18 years and younger. JAMA Pediatrics, 168(2), 178. https://doi.org/10.1001/jamapediatrics.2013.4200

O’Connor, E. A., Evans, C. V., Burda, B. U., Walsh, E. S., Eder, M., & Lozano, P. (2017). Screening for obesity and intervention for weight management in children and adolescents. JAMA, 317(23), 2427. https://doi.org/10.1001/jama.2017.0332

Bray, G. A., Edelstein, S. L., Crandall, J. P., Aroda, V. R., Franks, P. W., Fujimoto, W., Horton, E., Jeffries, S., Montez, M. G., Mudaliar, S., Pi-Sunyer, F. X., White, N. H., & Knowler, W. C. (2012). Long-Term safety, tolerability, and weight loss associated with Metformin in the Diabetes Prevention Program Outcomes study. Diabetes Care, 35(4), 731–737. https://doi.org/10.2337/dc11-1299

Harborne, L. R., Sattar, N., Norman, J. E., & Fleming, R. (2005). Metformin and Weight Loss in Obese Women with Polycystic Ovary Syndrome: Comparison of Doses. The Journal of Clinical Endocrinology & Metabolism, 90(8), 4593–4598. https://doi.org/10.1210/jc.2004-2283

Abdalla, M. A., Shah, N., Deshmukh, H., Sahebkar, A., Östlundh, L., Al-Rifai, R. H., Atkin, S. L., & Sathyapalan, T. (2022). Impact of metformin on the clinical and metabolic parameters of women with polycystic ovary syndrome: a systematic review and meta-analysis of randomised controlled trials. Therapeutic Advances in Endocrinology and Metabolism, 13. https://doi.org/10.1177/20420188221127142

De Silva, V. A., Suraweera, C., Ratnatunga, S. S., Dayabandara, M., Wanniarachchi, N., & Hanwella, R. (2016). Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis. BMC Psychiatry, 16(1). https://doi.org/10.1186/s12888-016-1049-5

Carolan, A., Hynes-Ryan, C., Agarwal, S. M., Bourke, R., Cullen, W., Gaughran, F., Hahn, M. K., Krivoy, A., Lally, J., Leucht, S., Lyne, J., McCutcheon, R. A., Norton, M. J., O’Connor, K., Perry, B. I., Pillinger, T., Shiers, D., Siskind, D., Thompson, A., . . . O’Donoghue, B. (2024). Metformin for the Prevention of Antipsychotic-Induced Weight Gain: Guideline development and Consensus Validation. Schizophrenia Bulletin. https://doi.org/10.1093/schbul/sbae205